AEGiS-PRn: Advanced Viral Research to Present New Data at Upcoming HIV Conferences

Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Advanced Viral Research to Present New Data at Upcoming HIV Conferences

PRNewswire - November 2, 2000

NEW YORK, Nov. 2 /PRNewswire/ -- Advanced Viral Research announced today that new data on Reticulose, their flagship product for the treatment of HIV and other viral diseases will be presented at the National AIDS Treatment Advocacy Conference held by the National Minority AIDS Council in Dallas Texas, November 9th to 12th and at the Frontiers in Drug Development for Antiretroviral Therapies HIV DART 2000 December 17-21, 2000.

This very exciting development in the field of immune base therapies for HIV disease promises to lead towards new break-throughs in our therapeutic ability to control HIV for longer duration," said Dr. Shalom Hirschman, CEO of Advanced Viral Research.

"Reticulose has presently been used by more than 100 HIV patients and has been attributed with reducing a number of the devastating consequences of antiretroviral therapy. AIDS activists and clinicians have a historic opportunity to take full advantage of the recent developments at the FDA review process for immune-based therapies to encourage the development of Reticulose," said Jeannie Gibbs of the International HIV IBT Working Group, a coalition of AIDS treatment activists dedicated to the advancement of immune-based therapies for HIV disease. "I would welcome the opportunity to explore the clinical advantages of Reticulose. The forthcoming data seems very exciting," said Dr. Diana Williamson MD M.sc, Medical Director of Brooklyn Medical Arts HIV CARE Center, one of the largest outpatient care programs for HIV patients in North America. "Many patients have exhausted their clinician options and are anxious to explore other clinical avenues to improve their tolerance to antiretroviral therapies. This forthcoming examination of Reticulose by AVR may be the first step in this much needed process."

SOURCE The International HIV IBT Working Group

001102
PR001101

Copyright © 2000 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .